Effectiveness and Safety of Matrix-Associated Autologous Chondrocyte Implantation for the Treatment of Articular Cartilage Defects: A Real-World Data Analysis in Japan.

BACKGROUND

The effectiveness and safety of matrix-associated autologous chondrocyte implantation with an autologous periosteal flap (pMACI) remain unclear. The Japanese Ministry of Health, Labor, and Welfare requires postmarketing surveillance of all patients undergoing pMACI using the tissue-engineered product JACC.

PURPOSE

To evaluate the effectiveness and safety of pMACI for large articular cartilage defects (≥4 cm

STUDY DESIGN

Case series; Level of evidence, 4.

METHODS

Data were collected from patients who underwent pMACI between 2012 and 2019, with 2 years of follow-up. The primary outcomes were the Lysholm knee score and Knee injury and Osteoarthritis Outcome Score (KOOS) at 6, 12, and 24 months. Adverse events were assessed by physical examination, magnetic resonance imaging, and/or arthroscopy.

RESULTS

Overall, 232 knees in 225 patients who presented with trauma (198 knees) or osteochondritis dissecans (34 knees) in the medial (132 knees) and lateral (44 knees) femoral condyle, patella (25 knees), trochlea (86 knees), and tibial plateau (4 knees) were included. The mean age of the patients was 40.9 ± 15.0 years, with mean cartilage defects of 5.6 ± 2.4 cm

CONCLUSION

Treatment of large cartilage defects (≥4 cm

Déclaration de conflit d'intérêts

One or more of the authors has declared the following potential conflict of interest or source of funding: Y.U. is a consultant who receives institutional support from Japan Tissue Engineering Co., LTD. (Japan). Y.U. has received institutional support from Pfizer Japan, Inc. (Japan), Eli Lilly Japan KK (Japan), Ono Pharmaceutical Co., LTD. (Japan), Daiichi Sankyo Co., LTD. (Japan), Shionogi & Co., LTD. (Japan), Kaken Pharmaceutical Co., LTD. (Japan), Chugai Pharmaceutical Co., LTD. (Japan), Mochida Pharmaceutical Co., LTD. (Japan), Nippon Zoki Pharmaceutical Co., LTD. (Japan), Seikagaku Corporation (Japan), Taisho Pharmaceutical Holdings Co., LTD. (Japan), Hisamitsu Pharmaceutical Co., Inc. (Japan), and Stryker (Japan). R.K. is a consultant who receives institutional support from Medacta International (Japan) and Japan Tissue Engineering Co., LTD. (Japan). R.K. has received institutional support from Zimmer Biomet (Japan), Smith & Nephew (Japan), and Hirosaki Life Science Innovation, Inc. (Japan). AOSSM checks author disclosures against the Open Payments Database (OPD). AOSSM has not conducted an independent investigation on the OPD and disclaims any liability or responsibility relating thereto.